Physician profile
Lea A Menear
NPI 1003811183
$4,381.29
in general payments reported to CMS, 2019-2025
22 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $174 · 2021: $534 · 2022: $665 · 2023: $664 · 2024: $969 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,491.94 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $442.77 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $409.43 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $365.99 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $265.19 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $198.00 | 2020-2025 | Rocklatan, Tryptyr, Eysuvis |
| Dompe US, INC. | $187.97 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $175.41 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $169.50 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $118.49 | 2020-2023 | |
| Allergan, INC. | $107.35 | 2021-2022 | |
| Harrow Eye, LLC | $102.77 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $90.55 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $70.99 | 2024-2025 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $49.35 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $27.04 | 2020 | |
| Rxsight INC | $20.95 | 2022 | |
| Biotissue Holdings INC. | $20.25 | 2025 | |
| Coopervision INC. | $19.34 | 2022 | |
| Eyepoint US, INC. | $16.45 | 2019 | |
| Optos, INC. | $16.13 | 2019 | |
| Horizon Therapeutics Plc | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Menear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.